Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal

Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profile Robust complementary immune responses were induced, with no major interference observed Lyon, France – July 10, 2025 –  Osivax, a biopharmaceutical company …

Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836

Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 Final results expected in H2 2025 Lyon, France – June 5, 2025 –  Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that all participants have completed their final visit …

Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates

Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates   First Close of Series B financing raises €10 million Meiji Seika Pharma Co., Ltd joins as new international investor Proceeds will accelerate preclinical and clinical development of its broad-spectrum influenza vaccine candidates Lyon, France – March 4, 2025 –   Osivax, a …